ArticleMetabolism: clinical and experimental2016
Hyperlipidemia and the development of diabetic retinopathy: Comparison between type 1 and type 2 animal models.
Article in Metabolism: clinical and experimental, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Association between the triglyceride glucose index and diabetic retinopathy in type 2 diabetes: a meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Modulation of mitochondrial dysfunction: Mechanisms and strategies for the use of natural products to treat stroke.Neural regeneration research · 2026Article
- The association between maternal blood lipid trajectory and offspring preschool myopia in prospective and nested case‒control analyses.Lipids in health and disease · 2026Article
- Factors associated with diabetic retinopathy among patients with diabetes in rural Guangxi, China: a multicenter cross-sectional study.Frontiers in endocrinology · 2026Observational
- Lipidomic analysis of vitreous humor derived from patients with proliferative diabetic retinopathy.BMC ophthalmology · 2025Article
- Novel High-Resolution Lipidomes Could Serve as New Biomarkers for Diabetic Retinopathy: A Bidirectional and Mediated Mendelian Randomization Study.Journal of cellular and molecular medicine · 2025Article
- Association between free triiodothyronine and diabetic retinopathy: insights from a longitudinal cohort study and Mendelian randomization.Frontiers in endocrinology · 2025Article
- Detection Rate of Diabetic Retinopathy Before and After Implementation of Autonomous AI-based Fundus Photograph Analysis in a Resource-Limited Area in Belize.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Correlation between the atherogenic index of plasma and risk of diabetic retinopathy.Frontiers in medicine · 2025Article
- Association between Disorders of Lipid Metabolism and Oculopathy: An Overview.International journal of medical sciences · 2025Review
- Obtusin ameliorates diabetic retinopathy by inhibiting oxidative stress and inflammation.Psychopharmacology · 2024Article
- Long noncoding RNAs and metabolic memory associated with continued progression of diabetic retinopathy.Journal of diabetes · 2024Article
- Article
- Prevalence of diabetic retinopathy and its risk factors in rural patients with type 2 diabetes referring to Beijing Huairou Hospital, China.BMC ophthalmology · 2024Article
- Review
- Homocysteine and mitochondrial quality control in diabetic retinopathy.Eye and vision (London, England) · 2024Article
- Diabetic Retinopathy Leading to Blindness- A Review.Current diabetes reviews · 2024Review
- Mitochondrial Genome-Encoded Long Noncoding RNA Cytochrome B and Mitochondrial Dysfunction in Diabetic Retinopathy.Antioxidants & redox signaling · 2023Article
- Diabetic retinopathy: a comprehensive update on in vivo, in vitro and ex vivo experimental models.BMC ophthalmology · 2023Review
- Klotho: A new therapeutic target in diabetic retinopathy?World journal of diabetes · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
aimIn the pathogenesis of diabetic retinopathy, reactive oxygen species (ROS) are elevated in the retina and the mitochondria are damaged, resulting in accelerated apoptosis. Dyslipidemia is also considered as one of the major factors in its development, and our aim is to investigate the compounding effect of hyperlipidemia in retinopathy.
methodsRetinal ROS, mitochondrial damage and vascular pathology were investigated in Zucker diabetic fatty rats (ZDF, type 2 diabetes model), during the age that spans from hyperlipidemia/pre-hyperglycemia (6weeks), to severe hyperglycemia/moderate hyperlipidemia (~12weeks), and ultimately to severe hyperglycemia/hyperlipidemia (20-40weeks). For comparison, retina from streptozotocin-induced Wistar rats (type 1 diabetic for 10-40weeks) was analyzed.
resultsCompared to age-matched lean rats, despite increased retinal cytosolic ROS in 6-week-old ZDF rats, mitochondrial dysfunction and DNA damage were not detected, and in 12-week-old ZDF rats, retinal mitochondria were dysfunctional, but mtDNA damage and vascular pathology (cell apoptosis and degenerative capillaries) were not detectable. Retina from 20-week-old ZDF rats (hyperglycemic for 14weeks or less) had significant mitochondrial dysfunction, mtDNA damage and vascular pathology, and similar abnormalities were observed in 40-week-old ZDF rats. Although retinal mitochondrial dysfunction was observed in Wistar rats diabetic for 20weeks, mtDNA damage and vascular pathology were not detectable till the duration of diabetes was further extended.
conclusionsHyperlipidemia, in a hyperglycemic milieu, potentiates mitochondrial damage and augments the development of retinopathy. Control of dyslipidemia in pre-diabetic patients may prevent/delay the development and the progression of this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.